Monoclonal Antibodies For COVID-19

An Update on Best Practices

 

Target Audience

The educational design of this activity addresses the needs of infectious disease clinicians, internal medicine clinicians, and primary care providers, including physicians, nurse practitioners, and physician assistants, involved in the care of patients with mild or moderate coronavirus disease 2019 (COVID-19) who are at risk for clinical progression (eg, older patients, immunocompromised patients, patients with certain comorbidities).

 

Statement of Need/Program Overview

Real-world use of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) can be challenging due to constantly changing guidelines, barriers to care, and a limited window to treat patients diagnosed with COVID-19. Clinic models for identifying patients eligible for treatment and subsequently linking patients to care have been established with great success. Guidelines now include both oral and intravenous antivirals in addition to anti-SARS-CoV-2 mAbs, and clinicians must remain current on available therapies and treatment stratification and prioritization. Drs. Monica Gandhi and Lucy Horton discuss identification of patients with mild to moderate COVID-19, clinic models for linking patients to care, and barriers to care.

This activity is jointly provided by Global Education Group and Integritas.

 

This educational activity is supported by an educational grant from GlaxoSmithKline.

Image POC101
Current Evidence and Guidelines for Anti-SARS-CoV-2 Monoclonal Antibodies

Module 1

Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH
MODULE 1
Begin Activity

credit amount 0.25

credit type CME/CE

expiration 06/07/2023

Image POC101
Real-World Use of Anti-SARS-CoV-2 Monoclonal Antibodies

Module 2

Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH
MODULE 2
Begin Activity

credit amount 0.25

credit type CME/CE

expiration 06/07/2023

Resource

Monoclonal Antibodies for COVID-19

An Update on Best Practices